Physician profile
Navin S Nikam
NPI 1881853778
$4,240.49
in general payments reported to CMS, 2019-2025
14 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $288 · 2021: $566 · 2022: $520 · 2023: $1,491 · 2024: $464 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,108.95 | 2019-2024 | Impella |
| Boston Scientific Corporation | $555.14 | 2024-2025 | Avvigo Guidance System, General - Balloon Catheters |
| Inari Medical, INC. | $334.20 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Medtronic Vascular, INC. | $248.06 | 2019-2020 | |
| Penumbra, INC. | $240.29 | 2023 | Indigo System |
| Janssen Pharmaceuticals, INC | $210.93 | 2022-2023 | Xarelto |
| Shockwave Medical, INC | $139.97 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $137.99 | 2021 | |
| Pfizer INC. | $73.03 | 2023 | |
| Abbott Laboratories | $70.67 | 2020 | |
| Ekos Corporation | $64.94 | 2019 | |
| Medtronic, INC. | $24.42 | 2025 | Micra |
| Biotronik INC. | $22.92 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $8.98 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Nikam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.